DEEPGEN
R&D Solution
Fast-track your liquid biopsy research with a solution specifically designed for deep genomics and AI data exploration.
Download Details
DEEPGEN powered liquid biopsy offers dozens of different research applications across 5 clinical areas and 15 cancer types.
The genes and mutations tested have been previously demonstrated to be involved in cancer. We identified this core spectrum of genes and mutations as the most likely candidates as biomarkers for the development and/or recurrence of cancer.
The current standard to conduct research is custom built solutions which take years to build and cost hundreds and thousands of dollars and offer limited accuracy.
DEEPGEN is your custom solution to outperform any custom panel in accuracy be immediately ready to research and save more money with every single run.
cfdna Extraction optimization
Assay Development
NGS Refinement
Bioinformatics development
Assay Development
NGS Refinement
Bioinformatics development
4 hours
8 hours
4 hours
30 days
Included
Included
Included
Included
Included
Included
Included
Included
3 months
6 months
3 months
6 months
$90,000
$30,000
$45,000
Included
Included
Included
Included
Detects to 0.1% validated MAF
258
cfdna Extraction
Library preparation (per batch)
NGS
Bioinformatics analysis
cfdna Extraction
Library preparation (per batch)
NGS
Bioinformatics analysis
Included
Included
Included
$80
$300
$600
$250
Limit of Detection
Genes Covered
Detects down to 1% MAF
(variable)
cfdna Extraction optimization
Assay Development
NGS Refinement
Bioinformatics development
cfdna Extraction
Library preparation (per batch)
NGS
Bioinformatics analysis
3 months
6 months
3 months
6 months
4 hours
8 hours
4 hours
30 days
Included
Included
Included
Included
Included
Included
Included
Included
Assay Development
NGS Refinement
Bioinformatics development
cfdna Extraction
Library preparation (per batch)
NGS
Bioinformatics analysis
$90,000
$30,000
$45,000
$80
$300
$600
$250
Included
Included
Included
Included
Included
Included
Included
Limit of Detection
Genes Covered
Detects down to 1% MAF
(variable)
Detects to 0.1% validated MAF
258
cfdna Extraction optimization
cfdna Extraction
NGS
Bioinformatics analysis
Library preparation (per batch)
Assay Development
NGS Refinement
Bioinformatics development
3 months
4 hours
8 hours
Included
6 months
Included
Included
3 months
6 months
Included
Included
Included
4 hours
30 days
Included
Included
cfdna Extraction optimization
cfdna Extraction
NGS
Bioinformatics analysis
Library preparation (per batch)
NGS Refinement
Bioinformatics development
$90,000
$80
$300
Included
$30,000
Included
Included
$45,000
Included
Included
$600
$250
Included
Included
Limit of Detection
Detects down to 1% MAF
Detects to 0.1% validated MAF
Genes Covered
(variable)
258
For more information, please contact William Ricketts, PhD, Quantgene's Director of Clinical Affairs.
Email: wricketts@quantgene.com
Phone: 949-701-8381
Dr. Ricketts has been in diagnostic development for more than fifteen years. He has designed, developed, and launched several CLIA cleared tests for cancer and autoimmune disease. In this role, he has written protocols and worked extensively with physicians to validate new tests and technologies for use in the clinical laboratory.
Dr. Ricketts received his BA from the University of Virginia and his PhD from the University of CA-San Diego. He is currently a Society of Gynecologic Oncology member and the American Association of Cancer Researchers.
For more information, please contact William Ricketts, PhD, Quantgene's Director of Clinical Affairs.
Email: wricketts@quantgene.com
Phone: 949-701-8381
Dr. Ricketts has been in diagnostic development for more than fifteen years. He has designed, developed, and launched several CLIA cleared tests for cancer and autoimmune disease. In this role, he has written protocols and worked extensively with physicians to validate new tests and technologies for use in the clinical laboratory.
Dr. Ricketts received his BA from the University of Virginia and his PhD from the University of CA-San Diego. He is currently a Society of Gynecologic Oncology member and the American Association of Cancer Researchers.
